

MARKET REPORT



Market Access Impact: Myeloma (EU5)

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data



Market Access Impact: Myeloma (EU5)

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

We look forward to being of service to you.

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

Phone: +44 (0)7887 945155 or **Email:** pdb@bioportfolio.co.uk

Market Access Impact: Myeloma (EU5)

Market barriers affect nearly 20% of myeloma prescriptions. Is your brand losing market share?

We surveyed 150 European oncologists and haematologists to find out how market barriers affect the way they prescribe 8 myeloma drugs. The results show that half of those treatments lose market share overall while the other half make small net gains.

Find out why, and learn what your brand can do to regain lost share, in Market Access Impact: Myeloma (EU5).

The report covers major brands from Amgen, BMS/AbbVie, Celgene, Johnson & Johnson, and Novartis. You'll discover which brands see the biggest gains and losses from 7 different market barriers, which barriers help and hurt your brand the most, and which competitors you take share from and lose it to.

....

Top Takeaways

Half of brands are widely prescribed: Around 70% or more of the doctors surveyed prescribe 4 of the 8 brands covered. Over 90% of doctors prescribe the top brand.

Half of the surveyed brands gain share: The four most prescribed brands all see small barrier-related net increases, but the most prescribed brand gains nearly twice as much as any other.

The top barrier affects two brands disproportionately: Significantly more doctors experience this barrier with two of the least prescribed brands.

"Other" brands also gain: They take share from all of the surveyed brands, and in aggregate, see the third-largest net share gain.

Eliminating barriers would affect the middle of the market: Two middle-ranking brands would switch places, and the aggregate of "other" brands would move down the rankings.

Market access affects more prescriptions than other barriers: Taken together barriers related to market access drive a third of barrier-related prescription decisions.

Insight into 8 Major Myeloma Drugs

Darzalex (daratumumab; Johnson & Johnson)

Empliciti (elotuzumab; BMS/AbbVie)

Farydak (panobinostat; Novartis)

Imnovid (pomalidomide; Celgene)

Kyprolis (carfilzomib; Amgen)

<https://www.bioportfolio.co.uk/product/65305>
pdb@bioportfolio.co.uk to order

Revlimid (lenalidomide; Celgene)

Thalomid (thalidomide; Celgene)

Velcade (bortezomib; Johnson & Johnson)

Exploring Important Market Access Issues

Market Access Impact: Myeloma explores key issues affecting Myeloma drug manufacturers. You'll learn:

How barriers affect market access:

What brands do doctors prescribe the most?

How many prescriptions do barriers affect?

Which barriers have the biggest impact?

How barriers affect your brand:

How many doctors prescribe your brand? How many don't, but would consider it?

Why don't doctors prescribe your brand? What do they prescribe instead?

Which competing brands does your brand take market share from?

A Report Based on Expert Knowledge

A We surveyed 150 medical oncologists and haematologists—30 from each EU5 country (France, Italy, Germany, Spain, UK)—chosen from the largest community of validated physicians in the world.

All respondents have:

Been practicing for 2+ years

Prescribed at least one of the listed products

Seen at least 5 patients with multiple myeloma in total in the last month

We conducted the survey between September 5th and 8th, 2016.

MONEY BACK GUARANTEE!

At FirstWord, we stand behind our reports. If you're not completely satisfied, we'll refund your money. Guaranteed.

About FirstWord

FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.

FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company's success.

FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.

Additional Details

Publisher : FirstWord Pharma

Reference :

Number of Pages : 0

Report Format : PDF

Publisher Information :



FirstWord

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data

**Best Prices
Guaranteed**

bioportfolio.co.uk

BioPortfolio
Life Science Healthcare and Pharmaceutical
Global Market Research and Corporate Data

Table Of Contents for Market Access Impact: Myeloma (EU5) [Report Updated: 01-10-2016]

- 1. What are the market barriers 2. About this report3. About the survey4. Brands included in the survey5. Executive summary

How to Buy...

Market Access Impact: Myeloma (EU5) [Report Updated: 01-10-2016]

Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/65305>

Option 2 - Request a Proforma Invoice

Fill in the details below, and either **Scan** this page **and email** it to us at pdb@bioportfolio.co.uk or **Fax** it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

Your Name:

Job Title:

Your Email:

Your Contact Phone:

Company Name:

Address:

Post/Zip Code:

Country:

P.O. Number:

Any Other Instructions:

Pricing Options: (please tick one)

- \$4995** | Single User Price
- \$7495** | Global License Price

Payment Options: (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

Authorising Signature:

Option 3 - Phone Us on +44 (0)7887 945155

We will be delighted to give you our personal attention.